Last reviewed · How we verify

NCT04015635

The Role of the Immune and Inflammatory Systems in Hypertension

Status unknown Last updated 14 May 2021
What this trial tests

trial testing None involved in Hypertension in 160 participants. Status unknown.

Timeline
7 May 2019
Primary endpoint
1 September 2021
1 September 2021

Quick facts

Lead sponsorUniversity of Glasgow
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment160
Start date7 May 2019
Primary completion1 September 2021
Estimated completion1 September 2021
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Glasgow

Who can join

Adults 18 to 55, any sex, with Hypertension or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To define the cytokine and cellular immune signature of primary hypertension. Cross sectional clinical/laboratory study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Vascular phenotypes in early hypertension.
    Murray EC, Delles C, Orzechowski P, Renc P, et al · · 2023 · cited 7× · PMID 36528682 · DOI 10.1038/s41371-022-00794-7

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other University of Glasgow trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04015635.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing